Form 4: Vor Biopharma CFO Nathan Jorgensen Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Nathan Jorgensen, CFO of Vor Biopharma Inc., reports the disposition of 917 common stock shares to cover tax withholding obligations related to restricted stock units.
Summary
- On May 1, 2024, Nathan Jorgensen, the Chief Financial Officer of Vor Biopharma Inc., disposed of 917 shares of common stock.
- The shares were withheld to satisfy tax obligations related to the settlement of restricted stock units.
- The transaction price was $1.77 per share.
- Following the transaction, Jorgensen directly owns 190,237 shares of Vor Biopharma Inc. common stock.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting routine tax obligations related to executive compensation. It doesn't inherently signal positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a standard tax withholding procedure related to equity compensation.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of the stock transaction where 917 shares were disposed of to cover tax obligations. |
| 05/03/2024 | Date of signature by Katie Kazem, Attorney-in-Fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.